Document:USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013
From GxPlex
| Document information | |
|---|---|
| Reference | USA FDA Guidance for Industry -
Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 |
| Validity area | USA |
| Scope(s) | G |
| Document name | FDA Guidance for Industry -
Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring |
| Version / Revision | Aug-2013 |
| Status | Current |
| Document type | Official recommendation |
| Language(s) | EN |
| Description | Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring
Guidance for Industry |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
References
| Scope | Document part | Language | Preview | |
|---|---|---|---|---|
| USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 III - IV. | G | III - IV. | EN | III. OVERVIEW OF MONITORING METHODS
A. On-Site and Centralized Monitoring 1. On-Site Monitoring 2. Centralized Monitoring B. Examples of Alternative M… |
| USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 III B. 3. | G | III B. 3. | EN | III. OVERVIEW OF MONITORING METHODS
B. Examples of Alternative Monitoring Techniques […] 3. Source Data Verification and Corroboration The sponsor sho… |
| USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 IV A. | G | IV A. | EN | IV. RISK-BASED MONITORING
[…] A. Identify Critical Data and Processes to be Monitored […] Other types of data (e.g., covariates such as concomitant tr… |
| USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 IV A. Adherence | G | IV A. Adherence | EN | IV. RISK-BASED MONITORING
[…] A. Identify Critical Data and Processes to be Monitored […] • Adherence to protocol eligibility criteria designed to exc… |
| USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 IV A. Conduct | G | IV A. Conduct | EN | IV. RISK-BASED MONITORING
[…] A. Identify Critical Data and Processes to be Monitored […] • Conduct and documentation of procedures essential to trial… |
| USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 IV A. Verification | G | IV A. Verification | EN | IV. RISK-BASED MONITORING
[…] A. Identify Critical Data and Processes to be Monitored […] • Verification that informed consent was obtained appropriat… |
| USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 VI C. | G | VI C. | EN | VI. ADDITIONAL STRATEGIES TO ENSURE STUDY QUALITY
[...] C. Delegation of Monitoring Responsibilities to a CRO If a sponsor of an IND study delegates … |
| USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 VI D. | G | VI D. | EN | VI. ADDITIONAL STRATEGIES TO ENSURE STUDY QUALITY
[…] D. Clinical Investigator and Site Selection and Initiation In addition to regulatory requiremen… |
